Maytag vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Whirlpool-owned appliance brand with durability heritage; "Built-to-Last" washing machines and dryers competing with LG, Samsung, and GE Appliances for the mainstream premium appliance segment.
About
Maytag is an American appliance brand known for its durability and reliability positioning — producing washing machines, dryers, dishwashers, and refrigerators with a brand heritage built on the "Maytag Repairman" advertising campaign (positioning that the repairman is lonely because Maytag appliances never need repair). Founded in 1893 in Newton, Iowa by Frederick Maytag, the brand was acquired by Whirlpool Corporation (NYSE: WHR) in 2006 for $1.7 billion and operates as a distinct brand within Whirlpool's multi-brand portfolio alongside the Whirlpool flagship, KitchenAid, and other brands.\n\nMaytag's product lineup focuses on large home appliances: front-load and top-load washing machines, gas and electric dryers, dishwashers, and refrigerators. The brand is positioned as the "Built-to-Last" option within Whirlpool's portfolio — typically priced in the mid-to-upper range of the mainstream appliance market, below KitchenAid and premium brands but above entry-level products. Maytag appliances are known for features like the Commercial Technology washing machines that use commercial-grade parts.\n\nIn 2025, Maytag competes with GE Appliances (Haier), LG, Samsung, and Electrolux for the premium mainstream appliance market. The appliance market has faced headwinds from the post-COVID housing market slowdown — major appliance purchases are often tied to home moves or remodels, which slowed significantly in 2023-2024. Whirlpool, facing financial pressure, has been rationalizing its brand portfolio and manufacturing footprint. Maytag's 2025 strategy within Whirlpool focuses on the brand's durability and reliability positioning, targeting homeowners who prioritize dependability over cutting-edge features for core laundry and dishwashing appliances.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.